AbbVie Inc (ABBV)vsZimmer Biomet Holdings Inc (ZBH)
ABBV
AbbVie Inc
$257.12
+0.83%
HEALTHCARE · Cap: $454.36B
ZBH
Zimmer Biomet Holdings Inc
$93.49
+1.14%
HEALTHCARE · Cap: $17.97B
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 657% more annual revenue ($64.39B vs $8.51B). ABBV leads profitability with a 9.8% profit margin vs 9.5%. ABBV appears more attractively valued with a PEG of 0.52. ABBV earns a higher WallStSmart Score of 73/100 (B).
ABBV
Strong Buy73
out of 100
Grade: B
ZBH
Strong Buy67
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-69.4%
Fair Value
$151.82
Current Price
$257.12
$105.30 premium
Margin of Safety
+21.5%
Fair Value
$121.85
Current Price
$93.49
$28.36 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 40.0%
Earnings expanding 290.4% YoY
Conservative balance sheet, low leverage
Growing faster than its price suggests
Reasonable price relative to book value
Growing faster than its price suggests
Earnings expanding 33.8% YoY
Areas to Watch
Premium valuation, high expectations priced in
Distress zone — elevated risk
4.8% revenue growth
ROE of 6.4% — below average capital efficiency
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 10.2% demonstrates continued momentum. PEG of 0.52 suggests the stock is reasonably priced for its growth.
Bull Case : ZBH
The strongest argument for ZBH centers on Price/Book, PEG Ratio, EPS Growth. PEG of 0.62 suggests the stock is reasonably priced for its growth.
Bear Case : ABBV
The primary concerns for ABBV are P/E Ratio, Altman Z-Score. A P/E of 72.0x leaves little room for execution misses.
Bear Case : ZBH
The primary concerns for ZBH are Revenue Growth, Return on Equity, Piotroski F-Score.
Key Dynamics to Monitor
ZBH carries more volatility with a beta of 0.47 — expect wider price swings.
ABBV is growing revenue faster at 10.2% — sustainability is the question.
ABBV generates stronger free cash flow (3.2B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ABBV scores higher overall (73/100 vs 67/100) and 10.2% revenue growth. ZBH offers better value entry with a 21.5% margin of safety. Both earn "Strong Buy" and "Strong Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Zimmer Biomet Holdings Inc
HEALTHCARE · MEDICAL DEVICES · USA
Zimmer Biomet is a publicly traded medical device company. The company is headquartered in Warsaw, Indiana, where it is part of the medical devices business cluster.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?